Role of GGAP/PIKE-A in prostate cancer progression
Abstract:
The clinical behavior of prostate cancer is extremely heterogeneous, ranging from indolent disease to aggressive, metastatic cancer with rapid mortality. GGAP2 is a GTPase protein with a GTPase activating protein GAP domain at the C-terminus. It was reported that GGAP2, or PIKE-A, can activate Akt and inhibit apoptosis. The goal of this proposal is characterize the role of GGAP2 in prostate cancer progression. Our results indicate that GGAP2 expression is increased in prostate cancer. In addition, GGAP2 is mutated in human prostate cancer. The multiplicity of GGAP2 mutations imply that these mutations may emerge in an environment of the multifocal heterogeneity of prostate cancer tissues. According to our results these mutations can stimulate cancer cell proliferation and enhance GGAP2 activation, indicating that they may contribute to increased activity of GGAP2 in prostate cancer. In summary, GGAP2 may promote prostate cancer growth and progression via overexpression andor mutation and as such is an important therapeutic target.